Apogee Therapeutics (APGE) Total Non-Current Liabilities (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Total Non-Current Liabilities data on file, last reported at $37.3 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $37.3 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $37.3 million (changed N/A YoY), and the FY2025 annual result was $31.2 million, down 15.94% from the prior year.
• Total Non-Current Liabilities improved to $37.3 million in Q1 2026 per APGE's latest filing, from $31.2 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $41.4 million in Q3 2024 and troughed at $2.0 million in Q4 2022.
• A 5-year average of $25.9 million and a median of $28.5 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities soared 722.78% in 2023, then dropped 15.94% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $2.0 million in 2022, then soared by 722.78% to $16.3 million in 2023, then soared by 127.47% to $37.1 million in 2024, then retreated by 15.94% to $31.2 million in 2025, then climbed by 19.61% to $37.3 million in 2026.
• Business Quant data shows APGE's Total Non-Current Liabilities at $37.3 million in Q1 2026, $31.2 million in Q4 2025, and $39.8 million in Q3 2025.